Other Information
−Removed: During the three months ended March 31, 2025, no director or “officer” (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended June 30, 2025, no director or “officer” (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408(a) of Regulation S-K.
3.1 Second Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015 (File No.
2 unchanged sentences
3.4 Certificate of Designation of Series A Convertible Preferred Stock of the Company (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 19, 2020 (File No.
−Removed: Non- Employee Director Compensation Policy
+Added: General Release of Claims and Separation Agreement between the Company and John Trizzino, dated June 2 0, 2025
+Added: Consulting and Advisory Agreement between the Company and John Trizzino, dated May 27, 2025
+Added: Amended Collaboration Agreement between the Company and Takeda Pharmaceutical Company Limited, dated April 29, 2025
31.1* Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: 101 The following financial information from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in Inline Extensible Business Reporting Language (Inline XBRL):
−Removed: (i) the Consolidated Statements of Operations for the three-month periods ended March 31, 2025 and 2024, (ii) the Consolidated Statements of Comprehensive Loss for the three-month periods ended March 31, 2025 and 2024, (iii) the Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024, (iv) the Consolidated Statements of Changes in Stockholders’ Deficit for the three-month periods ended March 31, 2025 and 2024, (v) the Consolidated Statements of Cash Flows for the three-month periods ended March 31, 2025 and 2024, and (vi) the Notes to the Consolidated Financial Statements.
+Added: 101 The following financial information from our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, formatted in Inline Extensible Business Reporting Language (Inline XBRL):
+Added: (i) the Consolidated Statements of Operations for the three and six-month periods ended June 30, 2025 and 2024, (ii) the Consolidated Statements of Comprehensive Loss for the three and six-month periods ended June 30, 2025 and 2024, (iii) the Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024, (iv) the Consolidated Statements of Changes in Stockholders’ Deficit for the three and six-month periods ended June 30, 2025 and 2024, (v) the Consolidated Statements of Cash Flows for the six-month periods ended June 30, 2025 and 2024, and (vi) the Notes to the Consolidated Financial Statements.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
1 unchanged sentence
* Filed or furnished herewith.
+Added: † Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
+Added: The Company hereby agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of this exhibit.
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
NOVAVAX, INC.
−Removed: May 8, 2025 By:
+Added: August 6, 2025 By:
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: May 8, 2025 By:
+Added: August 6, 2025 By:
Executive Vice President, Chief Financial Officer and Treasurer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.